Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bioequivalence guidance accessibility

Executive Summary

FDA releases draft guidance regarding the agency's plans to make product-specific, bioequivalence study design guidance available to the public on FDA's Web site. Currently, ANDA applicants must request guidance from the agency and wait for a response. The agency is seeking public comments for product-specific bioequivalence recommendations. FDA's Office of Generic Drugs has touted this long-awaited guidance as a means to reduce correspondence (1"The Pink Sheet" March 26, 2007, p. 14)...

You may also be interested in...

FDA Draft Bioequivalence Guidance Draws Litany Of Brand Name Complaints

Brand firms are weighing in on product-specific draft guidance issued by FDA, which the agency hopes will allow generic drug firms to design bioequivalence studies for their ANDAs without having to consult with the Office of Generic Drugs (1"The Pink Sheet" June 11, 2007, In Brief). The draft guidances can be found on 2FDA's Web site

ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources

FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts